<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00114205</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000430930</org_study_id>
    <secondary_id>UVACC-HIC-10722</secondary_id>
    <secondary_id>UVACC-29303</secondary_id>
    <nct_id>NCT00114205</nct_id>
  </id_info>
  <brief_title>Surgery and Intrapleural Docetaxel in Treating Patients With Malignant Pleural Effusion</brief_title>
  <official_title>Phase I Trial of Intrapleural Docetaxel Administered Via an Implantable Catheter in Subjects With a Malignant Pleural Effusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving drugs, such as docetaxel, directly into the pleura after surgery to drain&#xD;
      the pleural effusion may help keep fluid from building up again.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects, best way to give, and best dose of&#xD;
      intrapleural docetaxel given after surgery in patients with malignant pleural effusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of intrapleural docetaxel in patients with&#xD;
           malignant pleural effusion.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity profile of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in plasma and pleural fluid from these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the response in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients undergo thorascopic surgery to drain the malignant pleural effusion. An intrapleural&#xD;
      catheter (Pleurx catheter) is then inserted for subsequent docetaxel instillation.&#xD;
      Approximately 24 hours after surgery, patients receive docetaxel intrapleurally over 3&#xD;
      minutes via the Pleurx catheter. The Pleurx catheter is then clamped for 4 hours and the&#xD;
      patient is placed in several different positions to ensure uniform distribution of docetaxel&#xD;
      throughout the pleural cavity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of intrapleural docetaxel until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at weeks 1 and 3 and then monthly&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 8-24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose by adverse event evaluation 1 month after treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics by serum and pleural fluid analyses through 1 month</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response by chest x-ray response and survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic thoracoscopy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed malignant pleural effusion (MPE)&#xD;
&#xD;
               -  Symptomatic disease&#xD;
&#xD;
          -  Candidate for thoracoscopic surgery for treatment of MPE&#xD;
&#xD;
               -  No known or suspected ipsilateral pleurodesis that would preclude surgery&#xD;
&#xD;
          -  No bilateral MPEs&#xD;
&#xD;
          -  No progressive extrapleural disease that is untreatable and/or resistant to systemic&#xD;
             treatment&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  ALT and/or AST ≤ 1.5 times upper limit of normal (ULN) (if alkaline phosphatase&#xD;
             normal) OR&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN (if ALT and/or AST normal)&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  INR ≤ 1.5&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.8 mg/dL&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for ≥ 1 month after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No history of severe hypersensitivity reaction to docetaxel or other drugs formulated&#xD;
             with polysorbate 80&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No concurrent systemic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R. Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2006</verification_date>
  <study_first_submitted>June 13, 2005</study_first_submitted>
  <study_first_submitted_qc>June 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2005</study_first_posted>
  <last_update_submitted>March 17, 2010</last_update_submitted>
  <last_update_submitted_qc>March 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2010</last_update_posted>
  <keyword>malignant pleural effusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

